Outcomes compared across three antihypertensive groups
| Outcome | Hydralazine | Labetalol | Nicardipine | P value |
| SBP change, mm Hg, median (Q1, Q3) | −13 (−34, 0) | −18 (−36 to –5) | −19.5 (−41,–3) | 0.353 |
| DBP change, mm Hg, Median (Q1, Q3) | −9 (−25, 0) | −9 (−20, 0) | −12.5 (−27, 0) | 0.002 |
| HE, mL, median (Q1, Q3) | 0.15 (−0.32, 2.83) | 0.04 (−0.88, 1.37) | 0.05 (−0.89, 1.55) | 0.552 |
| 6 month mortality, n (%) | 9 (13.9) | 81 (22.7) | 149 (26.4) | 0.056 |
| Length of stay, days, median (Q1, Q3) | 8 (5, 16) | 8 (4, 17.5) | 10 (6, 18) | 0.004 |
| Discharge mRS=0–3, n (%) | 28 (41.8) | 153 (40.7) | 210 (36.3) | 0.322 |
| 90-day mRS=0–3, n (%) | 34 (58.6) | 186 (65.3) | 272 (61.7) | 0.494 |
| 6 month mRS=0–3, n (%) | 35 (62.5) | 200 (71.5) | 272 (65.5) | 0.109 |
| 12 month mRS=0–3, n (%) | 33 (70.2) | 183 (73.2) | 262 (67.4) | 0.291 |
| Discharge to facility, n (%) | 13 (21.3) | 68 (18.8) | 141 (25.4) | 0.068 |
P value: Kruskal-Wallis test for continuous variables, χ2 test for categorical variables with significance set at <0.05. Discharge to facility defined as discharge to skilled nursing home, assisted living, outside hospital or acute care setting.
DBP, diastolic blood pressure; HE, haematoma expansion; mRS, modified Rankin Scale; Q1, lower quartile; Q3, upper quartile; SBP, systolic blood pressure.